INSM vs NAMS: fair value comparison
Insmed Incorporated and NewAmsterdam Pharma Company N.V. · Updated 2026-10-19
INSM's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. NAMS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, INSM currently ranks higher by quality score.
| INSM | NAMS | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $96.27 | $19.83 |
| 12-month range | $91.88–$211.41 | $19.83–$41.45 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #135 of 301 Healthcare | #137 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: INSM fair value analysis · NAMS fair value analysis